Oruka Therapeutics (NASDAQ:ORKA) Stock: Insider Lawrence Otto Klein Sells 25,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Klein sold 25,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $95.60, for a total transaction of $2,390,000.00. Following the transaction, the chief executive officer owned 923,128 shares in the company, valued at approximately $88,251,036.80. This represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Thursday, October 1st, Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $83.62, for a total transaction of $2,090,500.00.
• On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $234,680.92.
• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00.

Oruka Therapeutics Trading Down 1.5%

Shares of NASDAQ:ORKA traded down $1.44 on Monday, reaching $95.43. The company had a trading volume of 654,336 shares, compared to its average volume of 1,079,825. Oruka Therapeutics, Inc. has a 52-week low of $25.23 and a 52-week high of $115.51. The firm’s 50 day simple moving average is $88.47 and its 200-day simple moving average is $68.90. The firm has a market capitalization of $6.32 billion, a PE ratio of -47.01 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities research analysts predict that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ORKA shares. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, October 19th. Guggenheim reiterated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 26th. Wedbush reiterated an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Finally, HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently made changes to their positions in the stock. Nykredit A S purchased a new position in Oruka Therapeutics in the 2nd quarter worth $29,000. GAMMA Investing LLC lifted its position in Oruka Therapeutics by 201.6% during the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after acquiring an additional 250 shares during the period. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $91,000. Sterling Capital Management LLC grew its stake in Oruka Therapeutics by 839.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock valued at $138,000 after purchasing an additional 1,485 shares during the last quarter. Finally, Natural Investments LLC purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at about $202,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.